Skip to main content

Table 1 Comparison of the studies on the use of Tocilizumab treatment in FMF patients

From: Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever

  Fujikawa et al. (2013) [33] Serelis et al. (2015) [34] Hamanoue et al. (2015) [18] Yilmaz et al. (2015) [19] Umeda et al. (2015) [35] Our cases
Total number of patients 1 1 1 11 1 12
Adult/children 1/0 1/0 1/0 11/0 1/0 12/0
Duration of Tocilizumab treatment, mean (months) Not specified 48 41 57 9 18
Gene analysis
 M694V/M694V     7   4
 M694V/M680I     2   1
 M694I/- heterozygous 1      
 Other   Not specified 1 2 1 7
Indications for Tocilizumab treatment
 Amyloidosis   1 1 11   12
 Frequent attacks (fever, serositis) 1 1 1   1  
 Arthritis/spondylitis   1 1    
 Protracted myalgia      1  
 Henoch-Schonlein purpura       
 Colchicine intolerance/side effect       
Effect of Tocilizumab during follow up
 No attacks 1   Unknown 8 1 10
 Decrease number of attacks   1     1
 No response       1
 Proteinuria in patients with amyloidosis   decreased decreased Decreased in 7   9
Side effects None Unknown Unknown Elevation of liver enzymes, mild thrombocytopenia Not specified Transient diplopia, deterioration in hypertension